🇺🇸 FDA
Pipeline program

Solriamfetol Oral Tablet

2021-P-000509

Approved small_molecule terminated

Quick answer

Solriamfetol Oral Tablet for Excessive Sleepiness is a Approved program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Axsome Therapeutics
Indication
Excessive Sleepiness
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials